col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

202 Results       Page 1

Wiley: British Journal of Dermatology
  original article Date Title Authors   All Authors
1 [GO] 2023―Feb―10 Responses to AstraZeneca COVID-19 vaccines in patients with immune-mediated skin diseases
2 [GO] 2023―Jan―27 Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study Amanda Kvist-Hansen, Laura Pérez-Alós, Rownaq Fares Al-Sofi, Line Dam Heftdal, Sebastian Rask Hamm, Dina Leth Møller, et al. (+16)
3 [GO] 2023―Jan―20 Is vaccination against COVID-19 associated with psoriasis or eczema flare? Self-controlled case series analysis using data from the Clinical Practice Research Datalink (Aurum) Laura Adams, Georgina Nakafero, Matthew J Grainge, Tim Card, Christian D Mallen, Jonathan S Nguyen Van-Tam, et al. (+2)
4 [GO] 2023―Jan―20 Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey Sophia Quirke-McFarlane, John Weinman, Emma S Cook, Zenas Z N Yiu, Nick Dand, Sinead M Langan, et al. (+33)
5 [GO] 2023―Jan―20 Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination Lluís Puig
6 [GO] 2023―Jan―19 Non-adherence to immune-modifying therapies during Covid-19 pandemic: the crucial role of doctor-patient communication to avoid drug discontinuation Mario Valenti, Antonio Costanzo
7 [GO] 2023―Jan―08 Failure to detect SARS-CoV-2 in the sweat of COVID-19 patients at RNA and protein level Thilo Gambichler, Silke Goesmann, Vera Korte, Marina Skrygan, Friederike Harnischfeger, Christina H Scheel, et al. (+5)
8 [GO] 2022―Aug―16 COVID-19 pandemic associated chilblains. More link for SARS-CoV-2 and less evidence for high interferon type-1 systemic response Didier Bessis, Sophie Trouillet-Assant, Léo-Paul Secco, Nathalie Bardin, Brigitte Blanc, Véronique Blatière, et al. (+18)
9 [GO] 2022―Aug―02 Nailfold videocapillaroscopy and serum VEGF in probable COVID-19-induced chilblains: a cross-sectional study to assess microvascular impairment Yora Mostmans, Vanessa Smith, Maurizio Cutolo, Karin Melsens, Salomé Battist, Asma Benslimane, et al. (+4)
10 [GO] 2022―Jul―23 Cutaneous Manifestations of SARS-CoV -2 infection during the Delta and Omicron waves in 348,691 UK users of the UK ZOE COVID Study App Alessia Visconti, Benjamin Murray, Niccolò Rossi, Jonathan Wolf, Sebastien Ourselin, Tim D. Spector, et al. (+3)
11 [GO] 2022―Jul―06 P02: Toxic epidermal necrolysis after COVID-19 booster vaccination: is a mixed vaccination schedule a risk?
12 [GO] 2022―Jul―06 GIRFT01: The long-term costs of COVID-19 for patients with skin cancer: a retrospective single-centre review of multidisciplinary team skin cancer cases and outcomes from 2019 to 2021
13 [GO] 2022―Jul―06 P11: Leser-Trélat sign: can it follow COVID-19 infection?
14 [GO] 2022―Jul―06 RF02: Hospitalization from COVID-19 is most frequently observed in patients with atopic dermatitis treated with systemic corticosteroids, and in particular when systemic corticosteroids are used in combination with another immunomodulatory treatment: lessons from the global SECURE-AD registry
15 [GO] 2022―Jul―06 GIRFT03: The number needed to treat metric: a further marker of the impact of COVID-19 on malignant melanomas
16 [GO] 2022―Jul―06 O02: Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
17 [GO] 2022―Jul―06 P24: Benzalkonium chloride: a potential emerging allergen in the era of the COVID-19 pandemic
18 [GO] 2022―Jul―06 P19: Fast-track occupational health dermatology clinic for healthcare workers: trends and burden of occupational dermatoses during the COVID-19 pandemic
19 [GO] 2022―Jul―06 P49: A comparative analysis of cutaneous squamous cell carcinoma staging before and during the COVID-19 pandemic.
20 [GO] 2022―Jul―06 GIRFT02: The influence of the COVID-19 pandemic on Breslow thickness and outpatient malignant melanoma service provision in an Irish Dermatology centre
21 [GO] 2022―Jul―06 P47: Effects of the COVID-19 pandemic on quality of utilization of the 2-week wait skin cancer pathway
22 [GO] 2022―Jul―06 P42: Clinical, histopathological and dermatoscopic characterization of eruptive pseudoangioma developing after COVID-19 vaccination
23 [GO] 2022―Jul―06 P29: COVID-19 vaccination and leprosy: a UK hospital-based retrospective cohort study
24 [GO] 2022―Jul―06 P46: A case series of COVID-19 vaccination and lymphatic dysfunction
25 [GO] 2022―Jul―06 CPC08: New-onset pemphigus foliaceus following COVID-19 vaccine
26 [GO] 2022―Jul―06 CPC02: An unusual case of rash secondary to the COVID-19 vaccine is presented with a review of the literature
27 [GO] 2022―Jul―06 P04: Phototherapy to treat a COVID-19 vaccine reaction
28 [GO] 2022―Jul―06 CD15: The development of a semi-virtual patch testing service at a university hospital during the COVID -19 pandemic
29 [GO] 2022―Jul―06 BI05: Is a hybrid skin cancer surveillance service for organ transplant recipients feasible? Lessons from the pandemic
30 [GO] 2022―Jul―06 PA08: Survey of caregiver satisfaction with remote versus face-to-face consultations in a tertiary paediatric dermatology clinic during the COVID -19 pandemic
31 [GO] 2022―Jul―06 H19: Plica polonica: a Polish pandemic
32 [GO] 2022―Jul―06 BT23: The impact of the COVID -19 pandemic and use of teledermatology in specialty training: experience at two UK dermatology training centres
33 [GO] 2022―Jul―06 BT17: A 3-year review of an innovative teledermatology service in paediatric dermatology delivering results in the face of a pandemic backlog
34 [GO] 2022―Jul―06 DP17: Impact of the COVID -19 pandemic on melanoma staging in a Scottish health board
35 [GO] 2022―Jul―06 BT03 (P47): Effects of the COVID -19 pandemic on quality of utilization of the 2-week wait skin cancer pathway
36 [GO] 2022―Jul―06 BT24: The effect of the COVID -19 pandemic on teledermatology usage and practices in a major secondary care centre
37 [GO] 2022―Jul―06 DS07: Missing melanomas in England during the COVID -19 pandemic: 2488 fewer melanoma diagnoses in 2020 than in 2019
38 [GO] 2022―Jul―06 H07: A historical review of pandemics with a dermatological perspective
39 [GO] 2022―Jun―14 Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with Coronavirus Disease 2019: A case series from a large United States healthcare system Bethany Cucka, Bianca Biglione, Li Zhou, Elizabeth J. Phillips, Fatima Bassir, Upeka Samarakoon, et al. (+6)
40 [GO] 2022―Jun―02 Sweet-like syndrome and Multiple COVID-Arm syndrome following COVID-19 vaccines: “Specific” patterns in a series of 192 patients Anne-Sophie Darrigade, Bénédicte Oulès, Pierre Sohier, Marie-Laure Jullie, Philippe Moguelet, Annick Barbaud, et al. (+8)
41 [GO] 2022―Jun―02 Pernio and Early SARS-CoV-2 Variants: Natural History of a Prospective Cohort and the Role of Interferon Ashley T. Ng, John J. Moon, Olivia R. Steidl, Hailey Bussan, Jennifer M. Tran, George Luong, et al. (+10)
42 [GO] 2022―May―25 Heterogeneity of reports about the impact of the COVID -19 pandemic on melanoma diagnosis Francesco Ricci, Damiano Abeni
43 [GO] 2022―Feb―01 Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey Katie Bechman, Emma S. Cook, Nick Dand, Zenas Z.N. Yiu, Teresa Tsakok, Freya Meynell, et al. (+33)
44 [GO] 2022―Jan―27 Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients Haig Pakhchanian, Rahul Raiker, Melanie Wolf, Shannon C. Trotter
45 [GO] 2022―Jan―06 Do treatments for psoriasis increase the risk of hospital admission or death caused by COVID-19 infections?
46 [GO] 2022―Jan―06 Varied skin reactions after COVID-19 vaccination
47 [GO] 2021―Dec―17 Chilblain-like lesions during the COVID-19 outbreak
48 [GO] 2021―Nov―29 COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation M. Kasperkiewicz, R. Strong, K. Mead, M. Yale, D. Zillikens, D.T. Woodley, A. Recke
49 [GO] 2021―Nov―25 Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine T. Žagar, N. Hlača, I. Brajac, L. Prpić-Massari, S. Peternel, M. Kaštelan
50 [GO] 2021―Nov―13 Bullous pemphigoid after SARS-CoV-2 vaccination: Spike protein-directed immunofluorescence confocal microscopy and T cell receptor studies T. Gambichler, N. Hamdani, H. Budde, M. Sieme, M. Skrygan, L. Scholl, et al. (+10)
51 [GO] 2021―Nov―08 Should we look beyond the interferon signature in chilblain-like lesions associated with COVID-19? S.M. Pilkington, R.E.B. Watson
52 [GO] 2021―Nov―02 Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic S. Cazzaniga, L. Naldi
53 [GO] 2021―Nov―02 COVID-19 vaccines and skin manifestations V. Bataille, S. Puig
54 [GO] 2021―Nov―02 Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination T. Gambichler, C. Krogias, I. Tischoff, A. Tannapfel, R. Gold, L. Susok
55 [GO] 2021―Oct―08 Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak L. Frumholtz, J.-D. Bouaziz, M. Battistella, J. Hadjadj, R. Chocron, D. Bengoufa, et al. (+24)
56 [GO] 2021―Oct―06 Occupational dermatoses during the second COVID-19 pandemic wave: a UK prospective study of 805 healthcare workers J. M. Gao, R. Goiriz, S. Rajpopat, P. Goldsmith
57 [GO] 2021―Sep―29 A case of COVID-19 vaccination-associated forme fruste purpura fulminans J. Griss, S. Eichinger, S. Winkler, W. Weninger, P. Petzelbauer
58 [GO] 2021―Aug―24 Not relevant responses in the era of Covid-19 - are we underestimating dermatology life quality index values? N. Kearney, R. Hambly, A. Alsharqi, B. Kirby
59 [GO] 2021―Aug―16 Sunlight separately from vitamin D is associated with a lower risk of death from COVID-19
60 [GO] 2021―Jul―26 Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1,326,312 patients in France L. Penso, R. Dray-Spira, A. Weill, M. Zureik, E. Sbidian
61 [GO] 2021―Jul―14 Analysis of T cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in chilblain-like lesions patients during the COVID-19 pandemic C. Cassius, M. Merandet, L. Frumholtz, D. Bergerat, A. Samri, C. Grolleau, et al. (+10)
62 [GO] 2021―Jul―13 Cutaneous reactions after SARS-COV-2 vaccination: A cross-sectional Spanish nationwide study of 405 cases A. Català, C. Muñoz-Santos, C. Galván-Casas, M. Roncero Riesco, D. Revilla Nebreda, A. Solá-Truyols, et al. (+34)
63 [GO] 2021―Jul―06 GIRFT06: Dermatology high-cost drug management: pharmacists getting it right first time in COVID-19
64 [GO] 2021―Jul―06 DS26: COVID-19 and reduced detection of malignant melanoma in secondary dermatology services
65 [GO] 2021―Jul―06 DT04: Pandemic placement: delivering the dermatology undergraduate curriculum at a UK medical school during the COVID-19 crisis
66 [GO] 2021―Jul―06 BT10: Medical education in the COVID-19 era: a remote dermatology attachment
67 [GO] 2021―Jul―06 DS06: Contending with COVID-19 in a Mohs micrographic surgery service
68 [GO] 2021―Jul―06 P19: Cutaneous manifestations of COVID-19 in the UK: a registry of digital submissions from interdisciplinary healthcare professionals
69 [GO] 2021―Jul―06 DP16: Severe, ulcerative cold panniculitis following COVID-19 infection
70 [GO] 2021―Jul―06 DP08: Leprosy unmasked by COVID-19 infection: a new diagnosis of leprosy with development of type 1 reversal reaction
71 [GO] 2021―Jul―06 DS25: Pandemic pressures: the impact of COVID-19 on the 2-week-wait service at a regional skin oncology centre
72 [GO] 2021―Jul―06 P28: The effects of COVID-19 on undergraduate dermatology training: a qualitative study
73 [GO] 2021―Jul―06 BT19: The use of a novel teledermatology/teledermoscopy service to maintain a dermatology cancer service in the midst of the COVID-19 pandemic
74 [GO] 2021―Jul―06 BT18: A new era for teledermatology in the COVID-19 pandemic
75 [GO] 2021―Jul―06 BT16: Disaster-recovery modelling to shape services: a dermatology helpline as a telemedicine intervention during the initial surge of the COVID-19 pandemic
76 [GO] 2021―Jul―06 PD11: Access to phototherapy during the COVID-19 pandemic
77 [GO] 2021―Jul―06 BT14: Exploring the feasibility of a remote acne service: a report of a pilot study using the MySkinSelfie platform during the COVID-19 pandemic
78 [GO] 2021―Jul―06 BT09: Standard of patient-sent images in teledermatology 2-week-wait skin cancer clinics during the COVID-19 pandemic
79 [GO] 2021―Jul―06 BI08: Remote management of immunotherapy-induced bullous pemphigoid during the COVID-19 pandemic
80 [GO] 2021―Jul―06 DS14: Experience of using a scar-assessment tool to evaluate scars after Mohs surgery via virtual consultation during the COVID-19 pandemic
81 [GO] 2021―Jul―06 P57: Surprising trends in the detection of cutaneous malignancy during the COVID-19 pandemic
82 [GO] 2021―Jul―06 BT15: Evaluating paediatric dermatology telephone clinics during the COVID-19 pandemic in a UK cohort: a prospective study
83 [GO] 2021―Jul―06 DS23: A multicentre qualitative study of patients’ experience of skin surgery during the COVID-19 pandemic in the UK
84 [GO] 2021―Jul―06 DT07: The impact of the COVID-19 pandemic on dermatology ST3 application preparation: a national survey of junior doctors in the UK
85 [GO] 2021―Jul―06 BI07: The effect of the COVID-19 pandemic on immunosuppressed patients undergoing skin surveillance
86 [GO] 2021―Jul―06 O01: The impact of the COVID-19 pandemic on people with psoriasis: findings from a global patient-reported registry
87 [GO] 2021―Jul―06 P25: The impact of the second wave of the COVID-19 pandemic on the quality of life of patients with skin cancer
88 [GO] 2021―Jul―06 CD08: Occupational dermatoses during the second COVID-19 pandemic wave: an audit of 401 healthcare workers
89 [GO] 2021―Jul―06 P38: Mental health of patients with psoriasis during the COVID-19 pandemic: a cross-sectional study in a tertiary setting
90 [GO] 2021―Jul―06 PS06 (P38): Mental health of patients with psoriasis during the COVID-19 pandemic: a cross-sectional study in a tertiary setting
91 [GO] 2021―Jul―06 BT12: The environmental impact of teledermatology in the COVID-19 pandemic: a silver lining
92 [GO] 2021―Jul―06 CD07: A survey of the incidence of skin problems in a cohort of hospital staff during the COVID-19 pandemic: can this help plan future services?
93 [GO] 2021―Jul―06 DT03: Diversifying educational resources during the COVID-19 pandemic: delivering educational dermatology podcasts and webinars for healthcare professionals
94 [GO] 2021―Jul―06 BT04: A new virtual inpatient dermatology electronic referral service: a timely answer to reducing cross-contamination during the COVID-19 pandemic?
95 [GO] 2021―Jul―06 DT02: What has been the impact of COVID-19 redeployment on dermatology trainees’ professional identity? An interpretative phenomenological study
96 [GO] 2021―Jul―06 P21: Practising dermatology in the era of COVID-19: a tertiary centre’s experience of adapting to change
97 [GO] 2021―Jul―06 PD14: Treating field cancerization in a time of COVID-19: daylight photodynamic therapy is effective, socially distant and satisfactory to our most vulnerable patients
98 [GO] 2021―Jul―06 P46: Occupational dermatoses during COVID-19: effect on work and wellbeing
99 [GO] 2021―Jul―06 P62: An increase in Breslow thickness: coronavirus or coincidence?
100 [GO] 2021―Jul―06 PD05: Skin safety and efficacy of filtered far ultraviolet C for SARS-CoV-2 inactivation
101 [GO] 2021―Jul―06 CD09: A review of semi-virtual patch testing during the SARS-CoV-2 pandemic: practicalities and patient experience
102 [GO] 2021―Jul―06 Primary cutaneous anaplastic large cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination T. Gambichler, S. Boms, S. Hessam, I. Tischoff, A. Tannapfel, T. Lüttringhaus, et al. (+2)
103 [GO] 2021―Jul―06 P24: Dermatology medical student history taking via the telephone: a way to minimize disruption to medical education, particularly during a pandemic
104 [GO] 2021―Jul―06 P73: A novel approach to systemic monitoring in a pandemic
105 [GO] 2021―Jul―05 Yet another benefit from sunlight in the fight against COVID-19? R.L. McKenzie, J.B. Liley
106 [GO] 2021―Jul―03 在 2019 年新型冠状病毒疾病 (COVID-19) 疫情期间, 银屑病或关节病患者的隔离因治疗类型而异
107 [GO] 2021―Jul―03 Shielding behaviour in people with psoriasis or a joint condition during the COVID-19 pandemic differs by treatment type
108 [GO] 2021―Jun―15 Relapse of chilblain-like lesions during the second COVID-19 pandemic wave: a cohort follow-up T. Hubiche, F. Le Duff, E. Fontas, J. Rapp, C. Chiaverini, T. Passeron
109 [GO] 2021―Jun―11 Kawasaki-like Multisystem Inflammatory Syndrome Associated with Coronavirus disease 2019 in an Adult: A case report R. Dabas, G. Varadaraj, S. Sandhu, A. Bhatnagar, R. Pal
110 [GO] 2021―Jun―09 COVID-19 outcomes in patients with autoimmune blistering disease E. Hwang, M.M. Tomayko
111 [GO] 2021―May―25 COVID-19-associated multisystem inflammatory syndrome in adults with Kawasaki disease-like cutaneous manifestations M. Razmi T, T.P. Afra, T.P. Mohammed, P.T.M. Ashik, E. Sukesh
112 [GO] 2021―May―20 Forewarned is Forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-COV-2 vaccine uptake and global public health W.H. Bermingham, M.R. Ardern-Jones, A.P. Huissoon, M.T. Krishna
113 [GO] 2021―May―19 Skin checks and skin cancer diagnosis in Australian general practice before and during the COVID pandemic, 2011-2020 J. Roseleur, D.A. Gonzalez-Chica, J. Emery, N.P. Stocks
114 [GO] 2021―May―17 Rarity of cutaneous findings among asymptomatic to mildly symptomatic COVID-19 patients admitted to a COVID Care facility in Delhi, India: An observational study A. Khurana, A. Mittal, R. Jain, A. Mishra, S.R. Mathachan
115 [GO] 2021―May―13 Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease A. Al-Janabi, Z. Littlewood, C.E.M. Griffiths, H.J.A. Hunter, H. Chinoy, C. Moriarty, et al. (+2)
116 [GO] 2021―May―07 SARS-CoV-2 infection in patients with atopic dermatitis: a cross-sectional study C. Nguyen, K. Yale, F. Casale, A. Ghigi, K. Zheng, J.I. Silverberg, N.A. Mesinkovska
117 [GO] 2021―May―06 Psoriasis, COVID-19 and shielding G. Becher, A.D. Burden
118 [GO] 2021―May―05 Diagnosis of COVID-19 using skin rashes
119 [GO] 2021―May―03 The impact of the COVID-19 pandemic on skin cancer incidence and treatment in England, 2020 Z.C. Venables, S. Ahmed, T. Bleiker, J. Broggio, M. Kwiatkowska, N.J. Levell, et al. (+6)
120 [GO] 2021―Apr―27 Chilblain lesions after COVID-19 mRNA vaccine A. Pileri, A. Guglielmo, B. Raone, A. Patrizi
121 [GO] 2021―Apr―27 Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination A.M. Carballido Vázquez, B. Morgado
122 [GO] 2021―Apr―24 Pernio after COVID-19 Vaccination S. Lopez, P. Vakharia, T. Vandergriff, E.E. Freeman, R. Vasquez
123 [GO] 2021―Apr―10 Outcomes of COVID-19 in Patients with Skin Cancer R. Raiker, H. Pakhchanian, A. Hussain, M. Deng
124 [GO] 2021―Apr―09 Ultraviolet A Radiation and COVID-19 Deaths in the USA with replication studies in England and Italy M. Cherrie, T. Clemens, C. Colandrea, Z. Feng, D.J. Webb, R.B. Weller, C. Dibben
125 [GO] 2021―Mar―18 Recurrence of chilblains during a second contact with SARS-CoV-2: a case report S. Maanaoui, F. Salez, O. Carpentier
126 [GO] 2021―Mar―17 Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study Z.Z.N. Yiu, G. Harding, C.E.M. Griffiths, R.B. Warren, E. McMullen, H.J.A. Hunter
127 [GO] 2021―Mar―04 The skin as a target for SARS-CoV-2 infection: exploiting the web for suitable data L. Naldi
128 [GO] 2021―Mar―03 Cold and COVID: Recurrent Pernio during the COVID-19 Pandemic E.E. Freeman, D.E. McMahon, J.B. Lipoff, M. Rosenbach, S.R. Desai, M. Fassett, et al. (+4)
129 [GO] 2021―Feb―20 Intention of COVID-19 vaccination among psoriatic patients compared to immunosuppressed patients with other skin diseases and factors influencing their decision E. Sotiriou, K. Bakirtzi, I. Papadimitriou, E. Paschou, E. Vakirlis, A. Lallas, D. Ioannides
130 [GO] 2021―Feb―08 COVID-19 相关的皮肤疾病以及相关生物制剂
131 [GO] 2021―Feb―08 Association of COVID-19 with skin diseases and relevant biologics
132 [GO] 2021―Jan―29 SARS-CoV-2 Spike Protein Positivity in Pityriasis Rosea-like and Urticaria-like Rashes of COVID-19 E. Welsh, J.A. Cardenas-de la Garza, A. Cuellar-Barboza, R. Franco-Marquez, R.I. Arvizu-Rivera
133 [GO] 2021―Jan―17 Oral ivermectin for a scabies outbreak in a long-term-care facility: Potential value in preventing COVID-19 and associated mortality? C. Bernigaud, D. Guillemot, A. Ahmed-Belkacem, L. Grimaldi-Bensouda, A. Lespine, F. Berry, et al. (+6)
134 [GO] 2021―Jan―15 Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection A. Visconti, V. Bataille, N. Rossi, J. Kluk, R. Murphy, S. Puig, et al. (+9)
135 [GO] 2021―Jan―14 COVID-19-associated cutaneous manifestations: does HHV-6 play an etiological role? I. Abadías-Granado, A. Navarro-Bielsa, A.M. Morales-Callaghan, L. Roc, C.C. Suso-Estívalez, M. Povar-Echeverría, Y. Gilaberte
136 [GO] 2021―Jan―10 COVID-19 related dermatosis in November 2019. Could this case be Italy’s patient zero? R. Gianotti, M. Barberis, G. Fellegara, C. Galván-Casas, E. Gianotti
137 [GO] 2020―Dec―24 Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey S.K. Mahil, M. Yates, S.M. Langan, Z.Z.N. Yiu, T. Tsakok, N. Dand, et al. (+37)
138 [GO] 2020―Dec―16 SARS-CoV-2 has not been detected directly by electron microscopy in the endothelium of chilblain lesions: reply from the authors I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez Peralto, L. Requena, A. Torrelo
139 [GO] 2020―Dec―10 Response to Tembhre et al.: ‘Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2’ J.R. Gehlhausen, C.J. Ko, W. Damsky
140 [GO] 2020―Dec―04 Association of skin diseases, biological treatment and COVID-19 during the first wave of the pandemic M.A. Descalzo, I. Garcia-Doval
141 [GO] 2020―Nov―29 Impaired type I interferon response in SARS-CoV-2 infection: looking through the cutaneous window D. Bessis
142 [GO] 2020―Nov―06 Enhanced expression of ACE2 in psoriatic skin and its upregulation in keratinocytes by interferon-gamma: Implication of inflammatory milieu in skin tropism of SARS-CoV-2 M.K. Tembhre, A.S. Parihar, V.K. Sharma, S. Imran, N. Bhari, R. Lakshmy, A. Bhalla
143 [GO] 2020―Nov―05 Response to “Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic G. Murray, D. Roche, A. Ridge, C. Hackett, A.M. Tobin
144 [GO] 2020―Nov―03 Oral vesiculobullous lesions as an early sign of COVID-19: immunohistochemical detection of SARS-CoV-2 spike protein C.D. Soares, A. Mosqueda-Taylor, M.G.F. Carvalho, O.P. Almeida
145 [GO] 2020―Nov―02 COVID-19 疫情期间观察到的大多数冻疮与 COVID-19 感染无关
146 [GO] 2020―Nov―02 Most chilblains observed during the COVID-19 outbreak are not linked to COVID-19 infection
147 [GO] 2020―Oct―28 Occupational dermatoses during the Covid-19 pandemic: a multicentre audit in the UK and Ireland H. O’Neill, I. Narang, D.A. Buckley, T.A. Phillips, C.G. Bertram, T.O. Bleiker, et al. (+9)
148 [GO] 2020―Oct―26 Prurigo pigmentosa and new-onset type 1 diabetes in a black female patient testing positive for SARS-CoV-2 IgG K.M. Derrick, D.R. Mazori, E.R. Heilman, S.A. Glick
149 [GO] 2020―Oct―05 SARS-CoV-2 导致冠状病毒脚趾
150 [GO] 2020―Oct―05 SARS-CoV-2 causes Covid Toes
151 [GO] 2020―Oct―01 SARS-CoV-2 Has Not Been Detected Directly by Electron Microscopy in the Endothelium of Chilblain Lesions: reply from authors I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez Peralto, L. Requena, A. Torrelo
152 [GO] 2020―Oct―01 SARS-CoV-2 Has Not Been Detected Directly by Electron Microscopy in the Endothelium of Chilblain Lesions J.K. Brealey, S.E. Miller
153 [GO] 2020―Sep―25 Response to ‘No evidence of SARS-CoV-2 infection by polymerase chain reaction or serology in children with pseudo-chilblain’. Reply from the authors D. Caselli, M. Chironna, D. Loconsole, M. Aricò
154 [GO] 2020―Sep―24 Prevalence of mucocutaneous manifestations, oral and palmoplantar findings in 666 patients with COVID-19 in a field hospital in Spain A. Nuno-Gonzalez, P. Martin-Carrillo, K. Magaletsky, M.D. Martin Rios, C. Herranz Mañas, J. Artigas Almazan, et al. (+11)
155 [GO] 2020―Sep―03 A review of studies into skin symptoms of COVID-19
156 [GO] 2020―Sep―03 COVID-19 皮肤症状研究综述
157 [GO] 2020―Sep―02 Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea S.I. Cho, Y.E. Kim, S.J. Jo
158 [GO] 2020―Sep―01 COVID-19 Session
159 [GO] 2020―Sep―01 Illuminating, through immunohistochemistry, the link between SARS-CoV-2 and pernio (chilblains) D.A. Wetter
160 [GO] 2020―Aug―31 Paucity of COVID-19 Dermatology Literature from Low- and Middle-Income Countries R.S. Pendse, B.L. Schwartz, J.L. Jia, E.E. Bailey
161 [GO] 2020―Aug―28 COVID-19 in hidradenitis suppurativa patients X.T. Lima, M.A. Cueva, M.B. Alora
162 [GO] 2020―Aug―28 Response to “No evidence of SARS-CoV-2 infection by PCR or serology in children with pseudochilblain” S. Recalcati, S. Tonolo, F. Luzzaro, F. Fantini
163 [GO] 2020―Aug―15 Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned M. Baeck, D. Hoton, L. Marot, A. Herman
164 [GO] 2020―Aug―15 Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned: reply from authors I. Colmenero, C. Santonja, M. Alonso-Riaño, D. Andina, J.L. Rodríguez-Peralto, L. Requena, A. Torrelo
165 [GO] 2020―Aug―13 Co-Reactivation of Human Herpesvirus alpha Subfamily (HSV Ⅰ and VZV) in Critically Ill Patient with COVID-19 R. Xu, Y. Zhou, L. Cai, L. Wang, J. Han, X. Yang, et al. (+4)
166 [GO] 2020―Aug―13 Occupational Dermatology in the time of the Covid-19 pandemic: A report of experience from London and Manchester, United Kingdom F.J. Ferguson, G. Street, L. Cunningham, I.R. White, J.P. McFadden, J. Williams
167 [GO] 2020―Aug―13 Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains G. Battesti, V. Descamps Vincent
168 [GO] 2020―Aug―13 Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains: reply from authors L. Le Cleach, S. Fourati, E. Sbidian, M. Beylot-Barry
169 [GO] 2020―Jul―31 Cutaneous signs in SARS CoV-2 infection: A plea for more rigorous peer-review in the time of COVID-19 H. Kittler, P. Tschandl, W. Weninger
170 [GO] 2020―Jul―23 A Very Peculiar Practice: Dermatology in the era of Covid-19 S. Walsh, D. Creamer
171 [GO] 2020―Jul―22 The differing pathophysiologies that underlie COVID-19 associated perniosis and thrombotic retiform purpura: a case series C. Magro, J.J. Mulvey, J. Laurence, S. Sanders, N. Crowson, M. Grossman, et al. (+2)
172 [GO] 2020―Jul―22 High incidence of hand eczema in Danish school children following intensive hand hygiene during the COVID-19 pandemic - a nationwide questionnaire study A.B. Simonsen, I.F. Ruge, A.S. Q꫞, J.D. Johansen, J.P. Thyssen, C. Zachariae
173 [GO] 2020―Jul―06 Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on PCR and serology testing L. Le Cleach, L. Dousset, H. Assier, S. Fourati, S. Barbarot, C. Boulard, et al. (+15)
174 [GO] 2020―Jul―02 Identificadas las principales manifestaciones en la piel de la COVID-19
175 [GO] 2020―Jul―02 COVID-19 确诊患者的五种常见皮肤表现
176 [GO] 2020―Jul―02 Response to: “Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases”: Vesicular eruption in COVID-19 - to exclude varicella S.Y.D. Lim, H.L. Tey
177 [GO] 2020―Jul―02 “Vesicular eruption in COVID-19 - to exclude varicella”: reply from the authors A. Català, C. Galván Casas, G. Carretero Hernández, I. García-Doval
178 [GO] 2020―Jul―02 Five common skin manifestations of COVID-19 identified
179 [GO] 2020―Jul―02 Chilblain-like lesions during COVID-19 pandemic: a serological study on a case series L. Rizzoli, L. Collini, M. Magnano, S. Termine, R. Barcelli, S.D. Infusino, et al. (+4)
180 [GO] 2020―Jul―02 No evidence of SARS-Cov-2 infection by PCR or serology in children with pseudochilblain D. Caselli, M. Chironna, D. Loconsole, L. Nigri, F. Mazzotta, D. Bonamonte, M. Aricò
181 [GO] 2020―Jun―29 Global Hidradenitis Suppurativa COVID-19 Registry: A Registry to Inform Data-Driven Management Practices H.B. Naik, R. Alhusayen, J. Frew, S. Guilbault, J.R. Ingram, M.A. Lowes, et al. (+4)
182 [GO] 2020―Jun―25 COVID-19 chilblain-like lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a PCR-negative patient C. Santonja, F. Heras, L. Núñez, L. Requena
183 [GO] 2020―Jun―22 Sars-CoV-2 infection: the same virus can cause different cutaneous manifestations: reply from authors C. Galván-Casas, A. Catalá, G. Carretero Hernández, I. Garcia-Doval
184 [GO] 2020―Jun―20 SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases I. Colmenero, C. Santonja, M. Alonso-Riaño, L. Noguera-Morel, A. Hernández-Martín, D. Andina, et al. (+4)
185 [GO] 2020―Jun―17 SARS-CoV-2 infection: the same virus can cause different cutaneous manifestations: reply from the authors C. Galván Casas, A. Català, G. Carretero Hernández, I. García-Doval
186 [GO] 2020―Jun―15 Risk of infections in psoriasis. A lesson to learn during the SARS -CoV-2 pandemic L. Naldi
187 [GO] 2020―Jun―13 Sars-CoV-2 infection: the same virus can cause different cutaneous manifestations F. Drago, G. Ciccarese, A. Rebora, S.I. Muzic, A. Parodi
188 [GO] 2020―Jun―05 Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic C.H. Earnshaw, H.J.A. Hunter, E. McMullen, C.E.M. Griffiths, R.B. Warren
189 [GO] 2020―Jun―01 Bullous skin disease patients in a high-epidemic COVID-19 area, Bergamo, Italy A. Carugno, P. Sena, F. Raponi, E. Robustelli Test, P. Vezzoli
190 [GO] 2020―Jun―01 Cutaneous manifestations in patients with COVID-19: A preliminary review of an emerging issue A.V. Marzano, N. Cassano, G. Genovese, C. Moltrasio, G.A. Vena
191 [GO] 2020―Jun―01 Emergency management of 2019 novel coronavirus: implications for the dermatology department J. Tao, Z. Song, L. Yang, C. Huang, A. Feng, X. Man
192 [GO] 2020―May―29 Absence of Skin of Colour Images in Publications of COVID-19 Skin Manifestations J.C. Lester, J.L. Jia, L. Zhang, G.A. Okoye, E. Linos
193 [GO] 2020―May―29 Virtual melanoma checks during a pandemic M. Janda, S.M. Swetter, C. Horsham, H.P. Soyer
194 [GO] 2020―May―27 Further evidence that chilblains are a cutaneous manifestation of COVID-19 infection M. Hughes, S. Rogers, G. Lepri, C. Bruni, M. Matucci-Cerinic
195 [GO] 2020―May―14 Thrombotic occlusive vasculopathy in skin biopsy from a livedoid lesion of a COVID-19 patient M. Llamas-Velasco, P. Muñoz-Hernández, J. Lázaro-González, A. Reolid-Pérez, B. Abad-Santamaría, J. Fraga, E. Daudén-Tello
196 [GO] 2020―Apr―30 Cutaneous lesions in a patient with COVID-19: are they related? B. Ahouach, S. Harant, A. Ullmer, P. Martres, E. Bégon, L. Blum, et al. (+2)
197 [GO] 2020―Apr―29 Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic S.K. Mahil, Z.Z.N. Yiu, K.J. Mason, N. Dand, B. Coker, D. Wall, et al. (+16)
198 [GO] 2020―Apr―29 Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases C. Galván Casas, A. Català, G. Carretero Hernández, P. Rodríguez-Jiménez, D. Fernández Nieto, A. Rodríguez-Villa Lario, et al. (+19)
199 [GO] 2020―Apr―28 The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience P. Gisondi, P. Facheris, P. Dapavo, S. Piaserico, A. Conti, L. Naldi, et al. (+3)
200 [GO] 2020―Apr―17 Phototherapeutic approach to dermatological patients during the 2019 Coronavirus pandemic: Real-life Data from the Italian Red Zone A. Pacifico, M. Ardigò, P. Frascione, G. Damiani, A. Morrone
201 [GO] 2020―Apr―07 Adverse Skin Reactions Among Healthcare Workers During the Coronavirus Disease 2019 Outbreak: A Survey in Wuhan and Its Surrounding Regions P. Lin, S. Zhu, Y. Huang, L. Li, J. Tao, T. Lei, et al. (+17)
202 [GO] 2020―Mar―06 Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department J. Tao, Z. Song, L. Yang, C. Huang, A. Feng, X. Man

202 Results       Page 1


Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.029 sec